At a glance
- Originator Sanofi-Synthelabo
- Class Gastrokinetics
- Mechanism of Action Beta 3 adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Gastrointestinal disorders
Most Recent Events
- 28 Mar 2000 No-Development-Reported for Gastrointestinal disorders in France (Unknown route)
- 28 Mar 2000 No-Development-Reported for Gastrointestinal disorders in Italy (Unknown route)
- 30 Aug 1999 Sanofi has merged with Synthélabo to form Sanofi-Synthélabo